J Clin Oncol 2016 05 22;34(15):1723-31. Epub 2016 Feb 22.
Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier RodrÃguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France.